title: Successful crizotinib retreatment after crizotinib-induced interstitial lung disease.
authors.affiliation: Department of Respiratory Medicine, Tohoku University Graduate School of Medicine, Sendai, Japan.
authors.forename: Satoru
authors.initials: S
authors.lastname: Yanagisawa
authors.forename: Akira
authors.initials: A
authors.lastname: Inoue
authors.forename: Akira
authors.initials: A
authors.lastname: Koarai
authors.forename: Manabu
authors.initials: M
authors.lastname: Ono
authors.forename: Tokiwa
authors.initials: T
authors.lastname: Tamai
authors.forename: Masakazu
authors.initials: M
authors.lastname: Ichinose
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy* / Q000235:genetics; D000077192:Adenocarcinoma of Lung; D000077547:Crizotinib; D005260:Female; D006801:Humans; D017563:Lung Diseases, Interstitial / Q000139:chemically induced*; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000235:genetics; D008875:Middle Aged; D009154:Mutation; D015514:Oncogene Proteins, Fusion / Q000235:genetics; D047428:Protein Kinase Inhibitors / Q000009:adverse effects*; D011720:Pyrazoles / Q000009:adverse effects*; D011725:Pyridines / Q000009:adverse effects*; D019233:Retreatment
chemical_list: C522504:EML4-ALK fusion protein, human; D015514:Oncogene Proteins, Fusion; D047428:Protein Kinase Inhibitors; D011720:Pyrazoles; D011725:Pyridines; D000077547:Crizotinib